A possible underlying mechanism is based on TGF-β release by tumor cells, because of its high serum level characterizing GC patients that is negatively correlated with the frequency of NK cells expressing NKp46, NKp30 but also NKG2D and DNAM1 [114]. This evidence concerns the gene KLRK1 and gastric cancer.